Release Summary

Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck’s KEYTRUDA and Eisai’s HALAVEN in Metastatic Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium

Merck